{"id":927469,"date":"2026-04-30T00:43:21","date_gmt":"2026-04-30T00:43:21","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/927469\/"},"modified":"2026-04-30T00:43:21","modified_gmt":"2026-04-30T00:43:21","slug":"optimism-surrounds-praxis-precision-medicines-prax-amid-potential-fda-approval-for-ulixacaltamide","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/927469\/","title":{"rendered":"Optimism Surrounds Praxis Precision Medicines (PRAX) Amid Potential FDA Approval for Ulixacaltamide"},"content":{"rendered":"\n

Praxis Precision Medicines Inc. (NASDAQ:PRAX<\/a>) is one of the 10 best biotech stocks with highest upside potential<\/strong><\/a>.<\/p>\n

As of the close of play on April 24, the broader consensus sentiments towards Praxis Precision Medicines Inc. (NASDAQ:PRAX) remained strongly bullish. The stock received coverage from 16 analysts, 14 of whom assigned Buy ratings and 1 gave a Hold call. With just 1 Sell rating, it carries a median 1-year target price of $625.31, leading to an upside potential of more than 81% for investors. This makes it one of the standout names within the biotech space.<\/p>\n

\"\" <\/p>\n

Copyright: nexusplexus \/ 123RF Stock Photo<\/p>\n

On April 10, Raymond James assigned a Strong Buy rating to Praxis Precision Inc. (NASDAQ:PRAX). The firm set a target price of $815, which leads to a lucrative upside potential of more than 136% at the current level.<\/p>\n

The firm reflected on the prevailing bearish sentiment towards the stock, which it believes is based on a predetermined conclusion completely devoid of empirical evidence. It emphasized that the expected FDA approval of ulixacaltamide during early 2027 could act as a definitive commercial catalyst for the stock. The firm also believes that at the current valuation level, investors are significantly undervaluing the likelihood of formal regulatory success.<\/p>\n

Praxis Precision Medicines Inc. (NASDAQ:PRAX) is involved in developing therapies to cure disorders related to the central nervous system, which are characterized by neuronal excitation-inhibition imbalance. These disorders include epilepsy, movement disorders, and depression. The company utilizes its proprietary platforms like Cerebrum and Solidus to target such imbalances.<\/p>\n

While we acknowledge the potential of PRAX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the\u00a0best short-term AI stock<\/strong><\/a>.<\/p>\n

READ NEXT:\u00a0<\/strong>33 Stocks That Should Double in 3 Years<\/strong><\/a> and <\/strong>15 Stocks That Will Make You Rich in 10 Years<\/strong><\/a>.<\/strong><\/p>\n

Disclosure: None. Follow Insider Monkey on Google News<\/strong><\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"Praxis Precision Medicines Inc. (NASDAQ:PRAX) is one of the 10 best biotech stocks with highest upside potential. As…\n","protected":false},"author":2,"featured_media":927470,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4315],"tags":[259719,105,4326,39461,259717,259716,65337,259718,16,15],"class_list":{"0":"post-927469","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-10-best-biotech-stocks","9":"tag-health","10":"tag-medication","11":"tag-potential","12":"tag-praxis-precision-inc","13":"tag-praxis-precision-medicines-inc","14":"tag-raymond-james","15":"tag-target-price","16":"tag-uk","17":"tag-united-kingdom"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/116490889402183828","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/927469","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=927469"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/927469\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/927470"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=927469"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=927469"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=927469"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}